Rytary Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
What should I know before taking it?
RYTARY is contraindicated in patients: Currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. Hypertension can occur if these drugs are used concurrently [see Drug Interactions (7.1)].
What important warnings are listed?
May cause falling asleep during activities of daily living. (5.1)Avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal-emergent hyperpyrexia and confusion. (5.2)Cardiovascular Events: Monitor patients with a history of cardiovascular disease. (5.3)Hallucinations/Psychosis may occur. (5.4)Impulse Control Disorders: Consider dose reduction or stopping RYTARY if occurs. (5.5)May cause or exacerbate dyskinesia: Consider dose reduction. (5.6)
How is this medication usually taken?
Extended-release capsules: 23.75 mg carbidopa and 95 mg levodopa: blue and white capsule imprinted with IPX066 on the capsule cap and 95 on the capsule body.36.25 mg carbidopa and 145 mg levodopa: blue and light blue capsule imprinted with IPX066 on the capsule cap and 145 on the capsule body.48.75 mg carbidopa and 195 mg levodopa: blue and yellow capsule imprinted with IPX066 on the capsule cap and 195 on the capsule body.61.25 mg carbidopa and 245 mg levodopa: blue capsule imprinted with IPX066 on the capsule cap and 245 on the capsule body.
What side effects are listed?
The following serious adverse reactions are discussed below and elsewhere in the labeling: Falling Asleep During Activities of Daily Living and Somnolence [see Warnings and Precautions (5.1)] Withdrawal-Emergent Hyperpyrexia and Confusion [see Warnings and Precautions (5.2)] Cardiovascular Ischemic Events [see Warnings and Precautions (5.3)] Hallucinations/Psychosis [see Warnings and Precautions (5.4)] Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.5)] Dyskinesia [see Warnings and Precautions (5.6)] Vitamin B6 Deficiency and Seizures [see Warnings and Precautions (5.7)] Peptic Ulcer Disease [see Warnings and Precautions (5.8)] Glaucoma [see Warnings and Precautions.
What interactions are listed?
Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of RYTARY. (7.2, 7.3)
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c1f7cd4-de56-45c1-a734-5e77b4aeb6f7
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.